At Zoetis, we understand the special bond shared between people and their pets – and the importance of keeping our canine companions happy and healthy. Today we will focus on how we care for dogs from a dermatology perspective, just one of the many core areas of focus for Zoetis.
Products & Services Feature Stories
The U.S. Food and Drug Administration (FDA) has approved Simparica™, a once-monthly chewable flea and tick medication for dogs.
Clint Lewis, Executive Vice President and President, International Operations at Zoetis, shares his insights on the critical role that animal health plays in creating a safe and abundant food supply for a growing global population.
Zoetis marked the completion of a 19,000-square-foot, three-story expansion at its manufacturing site in Lincoln, Nebraska.
First targeted antibody therapy approved for control of clinical signs of atopic dermatitis in dogs
On September 2, the U.S. Department of Agriculture (USDA) granted Zoetis a conditional license for a vaccine to help fight porcine epidemic diarrhea virus (PEDv) in pigs.
This month, Zoetis launched EnlightTM, a new online, comprehensive management tool designed to help dairy producers who own Holstein cattle more efficiently manage herd genetics.
Targeting the global poultry industry's more than $3 billion in annual losses to coccidiosis, Zoetis introduced Rotecc™ Coccidiosis Management on January 28
In January, Zoetis launched the first and only Janus Kinase (JAK) inhibitor for veterinary use in the United States and Europe.
The Zoetis joint venture in Jilin, China announced on August 27 the launch of Rui Lan An™, a specialized vaccine to help control porcine reproductive and respiratory syndrome (PRRS).
Whether it is sending a client a text appointment reminder, ordering medications online using the Zoetis e-Commerce portal or sharing news of interest with clients on Facebook...
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.